Citing EpiPen Price Hike, Clinton Touts Plan To Base Prices On Comparative Value

August 24, 2016 at 7:09 PM
Democratic Presidential Nominee Hillary Clinton weighed in on Mylan's controversial price increase for EpiPens by touting her plan to invest in private comparative value and benefits research and use the results to hold drug companies accountable for justifying their price hikes. She called on Mylan to immediately reduce the price of EpiPens in a statement Wednesday (Aug. 24), saying there is no apparent justification for the cost. A day after Clinton blasted the company, Mylan announced it is reducing the...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.